November 24, 2016 - By Winifred Garcia · 0 Comments
Celgene Corp (NASDAQ:CELG) institutional sentiment increased to 1.11 in 2016 Q2. Its up 0.12, from 0.99 in 2016Q1. The ratio is better, as 478 funds started new or increased holdings, while 481 sold and decreased their holdings in Celgene Corp. The funds in our partner’s database now hold: 587.22 million shares, down from 619.66 million shares in 2016Q1. Also, the number of funds holding Celgene Corp in their top 10 holdings decreased from 73 to 69 for a decrease of 4. Sold All: 70 Reduced: 411 Increased: 418 New Position: 60.
Celgene Corporation is a biopharmaceutical company. The company has a market cap of $91.28 billion. The Firm together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. It has a 45.8 P/E ratio. The Company’s primary commercial stage products include REVLIMID (lenalidomide), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), POMALYST/IMNOVID (pomalidomide), VIDAZA, azacitidine for injection (generic version of VIDAZA), THALOMID (thalidomide), OTEZLA (apremilast) and ISTODAX (romidepsin).
The stock decreased 0.10% or $0.12 on November 23, hitting $120.85. About 4.84M shares traded hands. Celgene Corporation (NASDAQ:CELG) has risen 9.35% since April 22, 2016 and is uptrending. It has outperformed by 3.94% the S&P500.
Analysts await Celgene Corporation (NASDAQ:CELG) to report earnings on January, 26. They expect $1.42 earnings per share, up 42.00% or $0.42 from last year’s $1 per share. CELG’s profit will be $1.07B for 21.28 P/E if the $1.42 EPS becomes a reality. After $1.39 actual earnings per share reported by Celgene Corporation for the previous quarter, Wall Street now forecasts 2.16% EPS growth.
According to Zacks Investment Research, “Celgene Corp. is an independent biopharmaceutical company engaged primarily in the discovery, development and commercialization of orally administered, small molecule drugs for the treatment of cancer and immunological diseases.”
Birchview Capital Lp holds 55.78% of its portfolio in Celgene Corporation for 779,051 shares. Oaktop Capital Management Ii L.P. owns 2.08 million shares or 49.78% of their US portfolio. Moreover, Selkirk Management Llc has 14.78% invested in the company for 248,250 shares. The Switzerland-based Bb Biotech Ag has invested 14.05% in the stock. Tiger Management L.L.C., a New York-based fund reported 379,140 shares.#img1#
Insider Transactions: Since January 1, 0001, the stock had 0 insider buys, and 10 insider sales for $46.59 million net activity.
Ratings analysis reveals 81% of Celgene Corporation’s analysts are positive. Out of 21 Wall Street analysts rating Celgene Corporation, 17 give it “Buy”, 0 “Sell” rating, while 4 recommend “Hold”. The lowest target is $83 while the high is $190. The stock’s average target of $136.89 is 13.27% above today’s ($120.85) share price. CELG was included in 38 notes of analysts from July 21, 2015. Wells Fargo maintained the stock with “Outperform” rating in Friday, December 4 report. On Friday, July 24 the stock rating was maintained by Cantor Fitzgerald with “Buy”. The stock has “Market Outperform” rating given by JMP Securities on Wednesday, March 9. Jefferies maintained the shares of CELG in a report on Wednesday, October 5 with “Buy” rating. The stock has “Outperform” rating given by Credit Suisse on Tuesday, April 19. The firm has “Buy” rating by Citigroup given on Thursday, September 29. The firm earned “Buy” rating on Thursday, January 7 by Suntrust Robinson. The rating was maintained by Suntrust Robinson on Friday, April 29 with “Buy”. The firm has “Strong-Buy” rating given on Tuesday, September 1 by Raymond James. Canaccord Genuity maintained the shares of CELG in a report on Friday, November 6 with “Buy” rating.
Celgene Corporation (Celgene), incorporated on April 17, 1986, is a biopharmaceutical company. The Firm together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. The Company’s primary commercial stage products include REVLIMID (lenalidomide), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), POMALYST/IMNOVID (pomalidomide), VIDAZA, azacitidine for injection (generic version of VIDAZA), THALOMID (thalidomide), OTEZLA (apremilast) and ISTODAX (romidepsin). The Company’s clinical trial activity includes trials across the disease areas of hematology, oncology, and inflammation and immunology. Celgene is involved in research in a range of scientific areas designed to deliver therapies, targeting areas, including intracellular signaling pathways, protein homeostasis and epigenetics in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies.
More notable recent Celgene Corporation (NASDAQ:CELG) news were published by: Fool.com which released: “Better Buy: Biogen Inc. vs. Celgene Corporation” on November 15, 2016, also Fool.com with their article: “Better Buy: Celgene Corporation vs. Bristol-Myers Squibb” published on November 18, 2016, Fool.com published: “3 Compelling Reasons to Buy Celgene Corporation Stock Right Now” on November 17, 2016. More interesting news about Celgene Corporation (NASDAQ:CELG) were released by: Fool.com and their article: “2 Reasons Celgene Corporation’s Future Just Got Brighter” published on October 28, 2016 as well as Fool.com‘s news article titled: “Celgene Corporation Is Firing on All Cylinders” with publication date: October 28, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Winifred Garcia